JP2018503401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503401A5 JP2018503401A5 JP2017556795A JP2017556795A JP2018503401A5 JP 2018503401 A5 JP2018503401 A5 JP 2018503401A5 JP 2017556795 A JP2017556795 A JP 2017556795A JP 2017556795 A JP2017556795 A JP 2017556795A JP 2018503401 A5 JP2018503401 A5 JP 2018503401A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- constant region
- chain constant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 39
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 39
- 102000005962 receptors Human genes 0.000 claims description 38
- 108020003175 receptors Proteins 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 11
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 9
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 7
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 claims description 7
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 claims description 7
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 7
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 claims description 7
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 claims description 7
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 7
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 101000648505 Homo sapiens Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 claims description 3
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 claims description 3
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 3
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 3
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 3
- 108010014401 TWEAK Receptor Proteins 0.000 claims description 3
- 102000016946 TWEAK Receptor Human genes 0.000 claims description 3
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 claims description 3
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 claims description 3
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 3
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 3
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 claims description 3
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 3
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims description 3
- 230000001640 apoptogenic effect Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102400001107 Secretory component Human genes 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims 5
- 230000019552 anatomical structure morphogenesis Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 22
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 241001024304 Mino Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105323P | 2015-01-20 | 2015-01-20 | |
| US62/105,323 | 2015-01-20 | ||
| PCT/US2016/014153 WO2016118641A1 (en) | 2015-01-20 | 2016-01-20 | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158581A Division JP2021006044A (ja) | 2015-01-20 | 2020-09-23 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503401A JP2018503401A (ja) | 2018-02-08 |
| JP2018503401A5 true JP2018503401A5 (enExample) | 2019-02-28 |
| JP7179464B2 JP7179464B2 (ja) | 2022-11-29 |
Family
ID=56417700
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556795A Active JP7179464B2 (ja) | 2015-01-20 | 2016-01-20 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2020158581A Pending JP2021006044A (ja) | 2015-01-20 | 2020-09-23 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2022142258A Active JP7499813B2 (ja) | 2015-01-20 | 2022-09-07 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2024090474A Withdrawn JP2024113039A (ja) | 2015-01-20 | 2024-06-04 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158581A Pending JP2021006044A (ja) | 2015-01-20 | 2020-09-23 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2022142258A Active JP7499813B2 (ja) | 2015-01-20 | 2022-09-07 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| JP2024090474A Withdrawn JP2024113039A (ja) | 2015-01-20 | 2024-06-04 | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10689449B2 (enExample) |
| EP (2) | EP3750918A1 (enExample) |
| JP (4) | JP7179464B2 (enExample) |
| KR (1) | KR102435324B1 (enExample) |
| CN (1) | CN107207601A (enExample) |
| AU (2) | AU2016209324B2 (enExample) |
| CA (1) | CA2972990A1 (enExample) |
| DK (1) | DK3247728T3 (enExample) |
| ES (1) | ES2806500T3 (enExample) |
| HU (1) | HUE051013T2 (enExample) |
| IL (3) | IL308212A (enExample) |
| NZ (1) | NZ732922A (enExample) |
| PL (1) | PL3247728T3 (enExample) |
| PT (1) | PT3247728T (enExample) |
| SG (2) | SG10202001779UA (enExample) |
| SI (1) | SI3247728T1 (enExample) |
| WO (1) | WO2016118641A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| CN109561681A (zh) * | 2016-07-20 | 2019-04-02 | Igm生物科学股份有限公司 | 多聚gitr结合分子及其用途 |
| SG11201900744SA (en) * | 2016-08-12 | 2019-02-27 | Janssen Biotech Inc | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| EP3360898A1 (en) * | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| JP7370580B2 (ja) * | 2017-04-06 | 2023-10-30 | ウニヴェルズィテート シュトゥットガルト | 結合および生物活性を改善した腫瘍壊死因子受容体（ｔｎｆｒ）結合タンパク質複合体 |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| CN108251443A (zh) * | 2018-01-23 | 2018-07-06 | 深圳市人民医院 | 一种tnfrsf10c重组质粒、制备方法及其应用 |
| WO2019157772A1 (zh) * | 2018-02-13 | 2019-08-22 | 和元生物技术（上海）股份有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
| CN111757941A (zh) * | 2018-02-26 | 2020-10-09 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CA3113268A1 (en) * | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | Multivalent igm- and iga-fc-based binding molecules |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| EP4582442A3 (en) | 2019-06-24 | 2025-10-29 | Universität Stuttgart | Tnfr2 agonists with improved stability |
| EP3907240A4 (en) * | 2019-08-02 | 2023-02-22 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Anti-tnfr2 antibody and use thereof |
| EP4013792A4 (en) | 2019-08-15 | 2023-10-04 | IGM Biosciences Inc. | IMMUNO-STIMULATING MULTIMER BINDING MOLECULES |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2021202863A1 (en) * | 2020-04-02 | 2021-10-07 | Promab Biotechnologies, Inc. | Human ror-1 antibody and anti-ror-1-car-t cells |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| CN115697419A (zh) * | 2020-05-12 | 2023-02-03 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与癌症疗法组合治疗癌症的用途 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| JP7203870B2 (ja) | 2021-01-18 | 2023-01-13 | イビデン株式会社 | 組電池用熱伝達抑制シート及び組電池 |
| EP4314046A4 (en) * | 2021-04-01 | 2025-03-19 | ModernaTX, Inc. | Mucosal expression of antibody structures and isotypes by mRNA |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| GB9015908D0 (en) | 1990-07-19 | 1990-09-05 | Celltech Ltd | Multivalent immunoglobulin |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| EP0642585B1 (en) | 1992-05-18 | 2005-12-28 | Genentech, Inc. | Activation of oligomerizing receptors by using fused receptor ligands |
| DK0614984T4 (da) | 1993-03-05 | 2010-12-20 | Bayer Healthcare Llc | Humane monoklonale anti-TNF-alfa-antistoffer |
| CA2139385C (en) | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
| AU697387C (en) | 1994-09-16 | 2006-03-02 | Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 | Polypeptides with Fc binding ability |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| KR100475492B1 (ko) | 1995-01-26 | 2005-03-14 | 바이오겐 아이덱 엠에이 인코포레이티드 | 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체 |
| IL116784A (en) | 1996-01-16 | 2000-01-31 | Hadasit Med Res Service | Device for examining viscoelasticity of a living or artificial tissue |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US20060269558A1 (en) | 1998-04-27 | 2006-11-30 | Murphy Gerald P | Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| DE60005135T3 (de) | 1999-01-07 | 2015-04-09 | Zymogenetics, Inc. | Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung |
| MXPA01008936A (es) | 1999-03-04 | 2003-07-21 | Human Genome Sciences Inc | Receptores 6 alfa y 6 beta del factor de necrosis tumoral. |
| JP2003528030A (ja) | 1999-03-11 | 2003-09-24 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アポトーシス誘導分子ｉｉ |
| DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| US7262005B1 (en) | 2000-02-04 | 2007-08-28 | Aurora Biosciences Corporation | Methods of protein destabilization and uses thereof |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| JP2004513878A (ja) | 2000-06-23 | 2004-05-13 | マキシジェン， インコーポレイテッド | 新規同時刺激分子 |
| JP2004502450A (ja) | 2000-07-10 | 2004-01-29 | ノバルティス アクチエンゲゼルシャフト | ターゲッティング遺伝子送達のための二官能性分子およびそれと複合化されたベクター |
| US6955717B2 (en) | 2001-05-01 | 2005-10-18 | Medimmune Inc. | Crystals and structure of Synagis Fab |
| JP3665316B2 (ja) * | 2001-05-18 | 2005-06-29 | 麒麟麦酒株式会社 | 抗ｔｒａｉｌ−ｒ抗体 |
| WO2002097046A2 (en) | 2001-05-25 | 2002-12-05 | Amgen, Inc. | B7 related protein-2 molecules and uses thereof |
| US20050214210A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| AU2002318364A1 (en) | 2001-06-14 | 2003-01-02 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
| AU2002361784A1 (en) | 2001-12-20 | 2003-07-09 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| GB0220205D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Neisseria toxin |
| DE60334247D1 (de) | 2002-11-27 | 2010-10-28 | Irm Llc | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen |
| EP1583773A1 (fr) | 2003-01-07 | 2005-10-12 | Biomerieux | Polypeptides f' du virus de l'hepatite c, epitopes et leurs applications diagnostiques et therapeutiques |
| EP1652925B1 (en) | 2003-07-15 | 2010-12-08 | Chugai Seiyaku Kabushiki Kaisha | IgM PRODUCTION BY TRANSFORMED CELLS AND METHODS FOR QUANTIFYING SAID IgM PRODUCTION |
| CA2534374A1 (en) | 2003-08-01 | 2005-02-10 | Enhan Technology Holdings International Co., Ltd. | Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury and proliferation and/or differentiation of neural stem cells in injured spinal cord |
| CN100427505C (zh) | 2004-08-19 | 2008-10-22 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途 |
| JP2008519030A (ja) | 2004-11-05 | 2008-06-05 | パリンゲン インコーポレーテッド | 抗体で誘導される細胞膜損傷 |
| WO2006063067A2 (en) | 2004-12-09 | 2006-06-15 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
| AU2006206234B2 (en) | 2005-01-21 | 2012-01-12 | Epitopix, Llc | Yersinia spp. polypeptides and methods of use |
| US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| US20060269556A1 (en) | 2005-04-18 | 2006-11-30 | Karl Nocka | Mast cell activation using siglec 6 antibodies |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
| US20060269567A1 (en) | 2005-05-16 | 2006-11-30 | Liu Yuen | Universal detoxifying composition |
| US20060269569A1 (en) | 2005-05-16 | 2006-11-30 | Liu Yuen | Universal antioncotic and pain relieving ointment |
| CA2609173C (en) | 2005-05-24 | 2015-03-17 | The United States Of America As Represented By The Secretary Of The Navy Naval Medical Research Center, Code 00L | Anti-class 5 fimbrial adhesin-based passive immunoprophylactic |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP2287196A3 (en) | 2006-01-13 | 2011-05-04 | Irm Llc | Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
| CN101074261A (zh) | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
| AU2007252295B2 (en) | 2006-05-19 | 2013-07-25 | Central Adelaide Local Health Network Incorporated | Selective modulation of receptor signalling |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| MY161894A (en) | 2006-09-08 | 2017-05-15 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| CN101965363A (zh) | 2006-11-02 | 2011-02-02 | 丹尼尔·J·卡鹏 | 具有活动部分的杂合免疫球蛋白 |
| WO2009030285A1 (en) | 2007-09-07 | 2009-03-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2219458B1 (en) | 2007-11-08 | 2015-07-15 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| RU2492871C2 (ru) | 2008-08-01 | 2013-09-20 | АКСИС, Инс. | Терапевтическое или профилактическое средство для лечения остеоартрита |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| BR112012025568A2 (pt) | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| CN103282495B (zh) | 2010-10-29 | 2017-06-09 | 第一三共株式会社 | 新的抗dr5抗体 |
| WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| WO2013049254A1 (en) | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
| US9382319B2 (en) * | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| UY34410A (es) | 2011-10-24 | 2013-05-31 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf |
| MX363819B (es) | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| EP3769789A1 (en) * | 2012-08-01 | 2021-01-27 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
| US9725517B2 (en) | 2012-10-26 | 2017-08-08 | Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences | Humanized monoclonal antibodies against the extracellular domain of human death receptor 5 |
| US9487773B2 (en) | 2013-03-01 | 2016-11-08 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Cell-based methods for coupling protein interactions and binding molecule selection |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| HK1222182A1 (zh) | 2013-05-07 | 2017-06-23 | F. Hoffmann-La Roche Ag | 三聚体抗原结合分子 |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| ES2923641T3 (es) | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
| AU2015206002B2 (en) | 2014-01-16 | 2020-06-11 | Mario Umberto Francesco MONDELLI | Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| WO2015145360A1 (en) | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| WO2016055432A2 (en) | 2014-10-08 | 2016-04-14 | F. Hoffmann-La Roche Ag | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| KR20240110000A (ko) | 2015-06-30 | 2024-07-12 | 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 | Btla 융합 단백질 작용제 및 이의 용도 |
| NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| WO2018017761A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| AU2017299610B2 (en) | 2016-07-20 | 2022-09-29 | Igm Biosciences, Inc. | Multimeric CD40 binding molecules and uses thereof |
| CN109561681A (zh) | 2016-07-20 | 2019-04-02 | Igm生物科学股份有限公司 | 多聚gitr结合分子及其用途 |
| CA3030647A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| CN117510643A (zh) | 2016-09-23 | 2024-02-06 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CN111757941A (zh) | 2018-02-26 | 2020-10-09 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| CA3113268A1 (en) | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | Multivalent igm- and iga-fc-based binding molecules |
| WO2020163646A1 (en) | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| EP4013792A4 (en) | 2019-08-15 | 2023-10-04 | IGM Biosciences Inc. | IMMUNO-STIMULATING MULTIMER BINDING MOLECULES |
| KR20220045030A (ko) | 2019-08-17 | 2022-04-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 |
| BR112022003282A2 (pt) | 2019-08-23 | 2022-05-24 | Igm Biosciences Inc | Glicovariantes de igm |
| US20220372142A1 (en) | 2019-09-19 | 2022-11-24 | Igm Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| KR20220122699A (ko) | 2020-01-06 | 2022-09-02 | 아이쥐엠 바이오사이언스 인코포레이티드 | 고도로 시알릴화된 다량체 결합 분자 |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| CN115697419A (zh) | 2020-05-12 | 2023-02-03 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与癌症疗法组合治疗癌症的用途 |
| EP4188951A4 (en) | 2020-07-27 | 2024-08-28 | IGM Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| US20240002526A1 (en) | 2020-11-17 | 2024-01-04 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
| MX2023009615A (es) | 2021-02-17 | 2023-08-24 | Igm Biosciences Inc | Moleculas de union anti-cd123 y usos de estas. |
| WO2022177870A1 (en) | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
-
2016
- 2016-01-20 US US15/544,873 patent/US10689449B2/en active Active
- 2016-01-20 IL IL308212A patent/IL308212A/en unknown
- 2016-01-20 DK DK16740686.7T patent/DK3247728T3/da active
- 2016-01-20 NZ NZ732922A patent/NZ732922A/en unknown
- 2016-01-20 IL IL284430A patent/IL284430B2/en unknown
- 2016-01-20 WO PCT/US2016/014153 patent/WO2016118641A1/en not_active Ceased
- 2016-01-20 JP JP2017556795A patent/JP7179464B2/ja active Active
- 2016-01-20 EP EP20168740.7A patent/EP3750918A1/en active Pending
- 2016-01-20 CA CA2972990A patent/CA2972990A1/en active Pending
- 2016-01-20 EP EP16740686.7A patent/EP3247728B1/en active Active
- 2016-01-20 PL PL16740686T patent/PL3247728T3/pl unknown
- 2016-01-20 ES ES16740686T patent/ES2806500T3/es active Active
- 2016-01-20 HU HUE16740686A patent/HUE051013T2/hu unknown
- 2016-01-20 KR KR1020177022773A patent/KR102435324B1/ko active Active
- 2016-01-20 SG SG10202001779UA patent/SG10202001779UA/en unknown
- 2016-01-20 PT PT167406867T patent/PT3247728T/pt unknown
- 2016-01-20 SI SI201630842T patent/SI3247728T1/sl unknown
- 2016-01-20 AU AU2016209324A patent/AU2016209324B2/en active Active
- 2016-01-20 CN CN201680006321.XA patent/CN107207601A/zh active Pending
- 2016-01-20 SG SG11201705116SA patent/SG11201705116SA/en unknown
-
2017
- 2017-06-21 IL IL253054A patent/IL253054B/en unknown
- 2017-06-30 US US15/638,748 patent/US9938347B2/en active Active
-
2020
- 2020-02-24 AU AU2020201323A patent/AU2020201323B2/en active Active
- 2020-04-28 US US16/861,102 patent/US11578131B2/en active Active
- 2020-09-23 JP JP2020158581A patent/JP2021006044A/ja active Pending
-
2022
- 2022-09-07 JP JP2022142258A patent/JP7499813B2/ja active Active
- 2022-11-14 US US18/055,340 patent/US20230203173A1/en not_active Abandoned
-
2024
- 2024-06-04 JP JP2024090474A patent/JP2024113039A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503401A5 (enExample) | ||
| JP7499813B2 (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| JP2019530640A5 (enExample) | ||
| JP2019528683A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP2007530588A5 (enExample) | ||
| CA2969888A1 (en) | Agonistic tnf receptor binding agents | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2019513370A5 (enExample) | ||
| EP2938637A2 (en) | Multivalent binding protein compositions | |
| EP2483310A1 (en) | Bispecific death receptor agonistic antibodies | |
| US20210380691A1 (en) | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders | |
| JP2020510659A5 (enExample) | ||
| CA3079363A1 (en) | Multispecific antigen binding proteins | |
| CA3125120A1 (en) | Antibody fusion protein, preparation method therefor and application thereof | |
| RU2016132370A (ru) | ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα | |
| CA3205985A1 (en) | Antibodies to tnfr2 and uses thereof | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| KR20220121822A (ko) | FcγRIIB 친화력이 강화된 항체 Fc 영역 | |
| TW202306984A (zh) | 抗ｃｄ１３７抗體及使用方法 | |
| WO2024179567A1 (zh) | Fap/4-1bb/cd40结合分子及其医药用途 | |
| KR20210046725A (ko) | 신규 암 면역요법 항체 조성물 | |
| WO2024114676A1 (zh) | Cldn18.2/4-1bb结合蛋白及其医药用途 | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| JPWO2021050656A5 (enExample) |